ArticleCancer chemotherapy and pharmacology2020

Phase I dose-escalation trial of the oral AKT inhibitor uprosertib in combination with the oral MEK1/MEK2 inhibitor trametinib in patients with solid tumors.

Anthony W Tolcher et al.PubMed ↗Publisher ↗

No numbers read from the abstract.